Literature DB >> 15035457

Pentoxyfylline in and prevention and treatment of chronic lung disease.

R Lauterbach1, D Pawlik, M Zembala, J Szymura-Oleksiak, I Lisowska-Miszczyk, D Kowalczyk, J Bury.   

Abstract

The anti-inflammatory effects of pentoxfylline are associated with a number of clinical benefits. These include reduction in mortality in patients who have undergone bone marrow transplants or suffer peritonitis. In infants with sepsis, a reduction in mortality has also been associated with pentoxyfylline administration. The anti-inflammatory effects of pentoxyfylline, as well as its bronchodilator, diuretic and respiratory muscle stimulant effects suggest it may have a useful role in BPD. Interim analysis of a prophylactic trial suggests pentoxyfylline may reduce treatment requirements after the neonatal period and that, in established BPD, pentoxyfylline and dexamethasone may be of similar efficacy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15035457     DOI: 10.1111/j.1651-2227.2004.tb03043.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  2 in total

1.  Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis.

Authors:  M K Park; H Babaali; L I Gilbert-McClain; M Stylianou; J Joo; J Moss; V C Manganiello
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2009-07       Impact factor: 0.670

Review 2.  Pentoxifylline in preterm neonates: a systematic review.

Authors:  Emma Harris; Sven M Schulzke; Sanjay K Patole
Journal:  Paediatr Drugs       Date:  2010-10-01       Impact factor: 3.022

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.